About InVivoMAb anti-rat TCR α/β The R73 monoclonal antibody reacts with a framework component of rat α/β TCR (alpha beta T cell receptor). The α/β TCR is expressed by most peripheral T cells, intestinal epithelial lymphocytes, and thymocytes. The R73 antibody has been reported to suppress the development of experimental autoimmune encephalitis and adjuvant arthritis. Moreover, R73 treatment was applied in the field of transplantation and prevented allograft rejection in heart, skin, small bowel, kidney, and cornea. InVivoMAb anti-rat TCR α/β Specifications IsotypeMouse IgG1, κ Recommended Isotype Control(s)InVivoMAb mouse IgG1 isotype control, unknown specificity Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenRat T Blasts and Erythrocytes Reported Applicationsin vivo administration FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<2EU/mg (<0.002EU/μg) Determined by LAL gel clotting assay Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein G Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze. Application ReferencesInVivoMAb anti-rat TCR α/β (CLONE: R73)Jörns A, Ishikawa D, Teraoku H, Yoshimoto T, Wedekind D, Lenzen S (2020). "Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes" BMC Med 18(1):33. PubMedThe cytokine IL-17 is a key player in autoimmune processes, while the cytokine IL-6 is responsible for the chronification of inflammation. However, their roles in type 1 diabetes development are still unknown.Inoki T, Yamagami S, Sakai R, Isobe M, Tsuru T, Kawashima H (2002). "Suppression of experimental autoimmune uveoretinitis by anti-alphabeta TCR monoclonal antibody" Jpn J Ophthalmol 46(5):518-24. PubMedTo evaluate the effects of anti-alphabeta T cell receptor monoclonal antibody (R73) on the induction of experimental autoimmune uveoretinitis (EAU) in rats.Schorlemmer HU, Kanzy EJ, Kurrle R, Seiler FR (1991). "Inhibitory effects of the anti-rat T-cell receptor (TCR) monoclonal antibody (MAb) R73 on various experimental autoimmune diseases" Agents Actions 34(1-2):161-4. PubMedThe anti-rat alpha/beta-TCR, MAb-R73 has been investigated as to its disease modifying activity on adjuvant arthritis (AA), on experimental allergic encephalomyelitis (EAE) and on a local graft versus host (GvH) reaction (popliteal lymph nodes = PLN) in Lewis or Brown-Norway rats. R73 was able to prevent the onset of the AA and even if therapy started after the establishment of AA the MAb was still able to reduce the degree of chronic inflammation and arrest its progress. Intravenous MAb-R73 application also reduced the signs of EAE and prevented mortality. This was even seen when the substance was given after the outbreak of the clinical symptoms or when the F(ab)2 fragment of this MAb was used. Also in the model of local GvH reaction R73 acted therapeutically and lowered the PLN weights.
